Cytokinetics, Incorporated
$70.71
+0.041%Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -10.8).
Valuation inputs: P/E -10.8, earnings yield N/A, momentum +0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +1.2%, ROIC -47.7%).
Profitability stack: net margin -8.9%, ROE +1.2%, ROIC -47.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +146.3%, momentum +0.0%, net margin -8.9%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Cytokinetics, Incorporated Market vs Earnings Trajectory
Loading price and EPS data...
Cytokinetics, Incorporated Fair Value Envelope
Cytokinetics, Incorporated Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Cytokinetics, Incorporated Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Cytokinetics, Incorporated Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Cytokinetics, Incorporated Street Expectations Map
Wall Street analysts project that CYTK stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 99.92, with estimates ranging from a low of 83.00 to a high of 140.00.
The consensus 1-year price target stands at 99.92, with estimates ranging from a low of 83.00 to a high of 140.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Cytokinetics, Incorporated Insider Positioning
During the last 12 months, insiders have sold $30.72M worth of CYTK shares, with no buying activity reported.
3 Months
0
0.00
195.7K
13.77M
-13.8M
-$13.77M
3-6 Months
0
0.00
77.7K
4.87M
-4.9M
-$4.87M
6-9 Months
0
0.00
154.3K
9.73M
-9.7M
-$9.73M
9-12 Months
0
0.00
61.2K
2.34M
-2.3M
-$2.34M
Top Buyers
No buying activity
Top Sellers
Callos Andrew
Officer: Evp, Chief Commercial Officer
$11.80M
Blum Robert I
Director, Officer: President & Ceo
$5.37M
Kaye Edward M. Md
Director
$3.66M
Malik Fady Ibraham
Officer: Evp Research & Development
$2.53M
Lee Sung
Officer: Evp, Chief Financial Officer
$2.14M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $30.72M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
CYTK has not reported any dividend yield values in the available annual periods.
cytk Dividend History
Learning Layer
Related Guides
Build conviction on CYTK by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.